For example, in ERBB2-overexpressing EGFR T790M lung cancer, we controlled and degraded ERBB2 and as well degraded EGFR, MET, and YES1 kinases that are known to drive this tumor resistance to drugs. This evidence concerns the gene ERBB2 and lung cancer.